---
title: "688192.SH (688192.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688192.SH/news.md"
symbol: "688192.SH"
name: "688192.SH"
parent: "https://longbridge.com/en/quote/688192.SH.md"
datetime: "2026-03-10T04:40:42.039Z"
locales:
  - [en](https://longbridge.com/en/quote/688192.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688192.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688192.SH/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/688192.SH/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/688192.SH/news.md)


# 688192.SH (688192.SH) — Related News

### [Dizal Pharmaceutical: Operating revenue of 801 million yuan in 2025, a year-on-year increase of 122.60%](https://longbridge.com/en/news/277174633.md)
*2026-02-27T09:38:36.000Z*
> Dizal Pharmaceutical released its performance report, with operating revenue of 801 million yuan in 2025, a year-on-year

### [Dizal Pharmaceutical: Loss in 2025 decreased by 82.6451 million yuan year-on-year](https://longbridge.com/en/news/277174705.md)
*2026-02-27T09:38:03.000Z*
> Dizal Pharmaceutical announced that the company achieved an operating income of RMB 801.1356 million in 2025, an increas

### [Dizal Pharmaceutical: 991,100 restricted shares from the 2020 stock option incentive will be listed for circulation](https://longbridge.com/en/news/275116952.md)
*2026-02-06T11:21:13.000Z*
> Dizal Pharmaceutical announced that 991,100 restricted shares from the 2020 option incentive plan will be listed and cir

### [More than 10 companies are queuing to go public in Hong Kong, "A+H" has become a new choice for pharmaceutical IPOs. Why are A-share pharmaceutical companies collectively heading to the Hong Kong stock market?](https://longbridge.com/en/news/274087884.md)
*2026-01-29T04:13:12.000Z*
> More than 10 pharmaceutical companies are lining up to go public in Hong Kong, forming a new "A+H" option. Dizal Pharmac

### [The newly revised Drug Administration Regulations will be implemented in May, strengthening the growth logic of the pharmaceutical sector](https://longbridge.com/en/news/274063167.md)
*2026-01-29T00:21:14.000Z*
> The newly revised "Regulations for the Implementation of the Drug Administration Law" will take effect on May 15, markin

### [New Stock News | Dizal Pharmaceutical submits application to Hong Kong Stock Exchange](https://longbridge.com/en/news/273581156.md)
*2026-01-24T09:49:04.000Z*
> According to the Hong Kong Stock Exchange's disclosure on January 23, Dizal Pharmaceutical (Jiangsu) Co., Ltd. (abbrevia

### [Dizal Pharmaceutical rushes to the Hong Kong stock market: expected revenue of 800 million, with a non-recurring loss of 850 million](https://longbridge.com/en/news/273569168.md)
*2026-01-24T01:19:32.000Z*
> Dizal Pharmaceutical plans to list on the Hong Kong Stock Exchange, expecting revenue of 800 million yuan in 2025, with 

### [](https://longbridge.com/en/news/273524101.md)
*2026-01-23T13:59:27.000Z*
> According to Hong Kong Stock Exchange documents: Dizal Pharmaceutical Co., Ltd. submitted a listing application to the H

### [](https://longbridge.com/en/news/273322923.md)
*2026-01-22T05:16:58.000Z*
> A-share innovative drug concept stocks fluctuated and declined, Aidea Pharma fell over 10%, TMSP dropped nearly 9%, ZBD,

### [Dizal Pharmaceutical: Plans to change its English name and amend the Articles of Association](https://longbridge.com/en/news/273198046.md)
*2026-01-21T08:38:23.000Z*
> Dizal Pharmaceutical announced that it will hold the 19th meeting of the second board of directors in 2026 to review and